Bone Therapeutics develops therapies to prevent and treat fractures by addressing underlying problems in bone regeneration. In November, the company’s allogeneic cell therapy product, ALLOB, received Orphan Drug Designation (ODD) from the EMA and the US FDA for the treatment of the genetic bone disorder osteogenesis imperfecta. Over the next two years, we expect frequent clinical development updates from Phase II and Phase III trials to boost awareness and interest in Bone Therapeutics&
14 Dec 2015
Clinical catalysts to boost awareness
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Clinical catalysts to boost awareness
Bone Therapeutics develops therapies to prevent and treat fractures by addressing underlying problems in bone regeneration. In November, the company’s allogeneic cell therapy product, ALLOB, received Orphan Drug Designation (ODD) from the EMA and the US FDA for the treatment of the genetic bone disorder osteogenesis imperfecta. Over the next two years, we expect frequent clinical development updates from Phase II and Phase III trials to boost awareness and interest in Bone Therapeutics&